Calcium Channel Blockade and Cardiovascular Prognosis in the European Trial on Isolated Systolic Hypertension

• Published in: Hypertension (Dallas, Tex. 1979) Vol. 32; no. 3; pp. 410 - 416
• Main Authors: Staessen, Jan A, Thijs, Lutgarde, Fagard, Robert H, Birkenhager, Willem H, Arabidze, Guramy, Babeanu, Speranta, Gil-Extremera, Blas, Bulpitt, Christopher J, Davidson, Christopher, de Leeuw, Peter W, Efstratopoulos, Aris D, Fletcher, Astrid E, Fogari, Roberto, Jaaskivi, Matti, Kawecka-Jaszcz, Kalina, Nachev, Choudomir, Petrie, James C, Seux, Marie-Laure, Tuomilehto, Jaakko, Webster, John, Yodfat, Yair
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01.09.1998; Hagerstown, MD Lippincott
• Subjects: Aged; Aged, 80 and over; Antihypertensive agents; Biological and medical sciences; Calcium Channel Blockers - administration & dosage; Cardiovascular Diseases - mortality; Cardiovascular system; Double-Blind Method; Drug Therapy, Combination; Enalapril - administration & dosage; Europe; Female; Humans; Hydrochlorothiazide - administration & dosage; Hypertension - drug therapy; Male; Medical sciences; Middle Aged; Nitrendipine - administration & dosage; Pharmacology. Drug treatments; Prognosis; Systole; Europe; Human; Hypertension; Systolic pressure; Prognosis; Nitrendipine; Calcium antagonist; Cardiovascular disease; Controlled therapeutic trial; Chemotherapy; Treatment; Follow up study; Antihypertensive agent; Dihydropyridine derivatives
• ISSN: 0194-911X; 1524-4563
• DOI: 10.1161/01.HYP.32.3.410

In the double-blind Systolic Hypertension in Europe (Syst-Eur) Trial, active treatment was initiated with nitrendipine (10 to 40 mg/d) with the possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d) titrated or combined to reduce sitting systolic blood pressure by at least 20 mm Hg to <150 mm Hg. In the control group, matching placebos were used similarly. In view of persistent concerns about the use of calcium channel blockers as first-line antihypertensive drugs, this report explored to what extent nitrendipine, administered alone, prevented cardiovascular complications. Age at randomization averaged 70.2 years and systolic/diastolic blood pressure 173.8/85.5 mm Hg. Of 2398 actively treated patients, 1327 took only nitrendipine (average dose, 23.4 mg/d), and 1042 progressed to other treatments including nitrendipine (n=757; 35.7 mg/d), enalapril (n=783; 13.4 mg/d), and/or hydrochlorothiazide (n=294; 21.0 mg/d). Compared with the whole placebo group (n=2297), patients receiving monotherapy with nitrendipine had 25% (P=0.05) fewer cardiovascular end points, and those progressing to other active treatments showed decreases (P<or=to0.01) in total mortality (40%), stroke (59%), and all cardiovascular end points (39%). Among the control patients, 863 used only the first-line placebo. Compared with this subgroup, patients receiving monotherapy with nitrendipine showed a nearly 50% (P<or=to0.004) reduction of all types of end points, including total and cardiovascular mortality. The full relative benefit from nitrendipine was seen as early as 6 months after randomization. To ascertain that the benefit conferred by the dihydropyridine was not due to selection bias, the 1327 patients remaining on monotherapy with nitrendipine were matched by gender, age, previous cardiovascular complications, and systolic blood pressure at entry with an equal number of placebo patients. In this analysis, nitrendipine reduced (P<or=to0.05) cardiovascular mortality by 41%, all cardiovascular end points by 33%, and fatal and nonfatal cardiac end points by 33%. Despite the limitations inherent in post hoc analyses, the present findings suggest that the calcium channel blocker nitrendipine, given as a single antihypertensive medication, prevents cardiovascular complications in older patients with isolated systolic hypertension. (Hypertension. 1998;32:410-416.)